Altimmune, Inc.Altimmune, Inc.Altimmune, Inc.

Altimmune, Inc.

No trades
See on Supercharts
Market capitalization
‪535.26 M‬USD
−1.64USD
‪−88.45 M‬USD
‪426.00 K‬USD
‪70.17 M‬
Beta (1Y)
2.32

About Altimmune, Inc.

CEO
Vipin K. Garg
Headquarters
Gaithersburg
Employees (FY)
59
Founded
1997
ISIN
US02155H2004
FIGI
BBG000FXML90
Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬

See all ideas 

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of ALT is 7.47 USD — it has decreased by 1.06% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Altimmune, Inc. stocks are traded under the ticker ALT.
Altimmune, Inc. is going to release the next earnings report on May 14, 2024. Keep track of upcoming events with our Earnings Calendar.
One year price forecast for Altimmune, Inc. has a max estimate of 35.00 USD and a min estimate of 12.00 USD.
ALT earnings for the last quarter are −0.39 USD whereas the estimation was −0.45 USD which accounts for 13.81% surprise. Estimated earnings for the next quarter are −0.46 USD. See more details about Altimmune, Inc. earnings.
Altimmune, Inc. revenue for the last quarter amounts to ‪362.00 K‬ USD despite the estimated figure of 857.00 USD. In the next quarter revenue is expected to reach ‪2.14 K‬ USD.
Yes, you can track Altimmune, Inc. financials in yearly and quarterly reports right on TradingView.
Like other stocks, ALT shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Altimmune, Inc. stock right from TradingView charts — choose your broker and connect to your account.
ALT reached its all-time high on Mar 14, 2006 with the price of 2724.00 USD, and its all-time low was 1.51 USD and was reached on Nov 19, 2019.
See other stocks reaching their highest and lowest prices.
As of Apr 16, 2024, the company has 59.00 employees. See our rating of the largest employees — is Altimmune, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Altimmune, Inc. EBITDA is ‪−83.03 M‬ USD, and current EBITDA margin is ‪−19.49 K‬%. See more stats in Altimmune, Inc. financial statements.